Sepsis-Induced Acute Kidney Injury

Critical Care Clinics

Volumn 31, Issue 4, 2015, Pages 649-660

  Mårtensson, Johan ^a,b   Bellomo, Rinaldo ^a,c  

^a AUSTIN HOSPITAL   (Australia)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Acute kidney injury; Inflammation; Renal replacement therapy; Sepsis

Indexed keywords

ACETYLSALICYLIC ACID; ALKALINE PHOSPHATASE; HISTONE ANTIBODY; HYPERTENSIVE FACTOR; NORADRENALIN; POLYMYXIN B; THROMBOMODULIN; VASOCONSTRICTOR AGENT;

ACUTE KIDNEY FAILURE; ANEMIA; BLOOD PRESSURE; CELL FUNCTION; CELL PROTECTION; CENTRAL VENOUS PRESSURE; COMORBIDITY; DISEASE SEVERITY; ERYTHROCYTE TRANSFUSION; EVOLUTIONARY ADAPTATION; FLUID THERAPY; HEMOPERFUSION; HUMAN; INNATE IMMUNITY; KIDNEY BLOOD FLOW; NONHUMAN; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; SEPSIS; SEPTIC SHOCK; ACUTE KIDNEY INJURY; ADAPTATION; COMPLICATION; GLOMERULUS; GLOMERULUS FILTRATION RATE; HYPOTENSION; KIDNEY TUBULE; MICROBIOLOGY; PATHOPHYSIOLOGY;

ACUTE KIDNEY INJURY; ADAPTATION, PHYSIOLOGICAL; BLOOD PRESSURE; ERYTHROCYTE TRANSFUSION; FLUID THERAPY; GLOMERULAR FILTRATION RATE; HUMANS; HYPOTENSION; KIDNEY GLOMERULUS; KIDNEY TUBULES; RENAL REPLACEMENT THERAPY; SEPSIS; VASOCONSTRICTOR AGENTS;

EID: 84942198159     PISSN: 07490704     EISSN: 15578232     Source Type: Journal    
DOI: 10.1016/j.ccc.2015.06.003     Document Type: Review

References (69)

1. Uchino S., Kellum J.A., Bellomo R., et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005, 294(7):813-818.
2. Murugan R., Karajala-Subramanyam V., Lee M., et al. Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival. Kidney Int 2010, 77(6):527-535.
3. Bagshaw S.M., Uchino S., Bellomo R., et al. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol 2007, 2(3):431-439.
4. Hoste E.A., Lameire N.H., Vanholder R.C., et al. Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. J Am Soc Nephrol 2003, 14(4):1022-1030.
5. Zhang Q., Raoof M., Chen Y., et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010, 464(7285):104-107.
6. Bosmann M., Ward P.A. The inflammatory response in sepsis. Trends Immunol 2013, 34(3):129-136.
7. Brun C., Munck O. Lesions of the kidney in acute renal failure following shock. Lancet 1957, 272(6969):603-607.
8. Lerolle N., Nochy D., Guerot E., et al. Histopathology of septic shock induced acute kidney injury: apoptosis and leukocytic infiltration. Intensive Care Med 2010, 36(3):471-478.
9. Langenberg C., Bagshaw S.M., May C.N., et al. The histopathology of septic acute kidney injury: a systematic review. Crit Care 2008, 12(2):R38.
10. Yang Q.H., Liu D.W., Long Y., et al. Acute renal failure during sepsis: potential role of cell cycle regulation. J Infect 2009, 58(6):459-464.
11. Zuk A., Bonventre J.V., Brown D., et al. Polarity, integrin, and extracellular matrix dynamics in the postischemic rat kidney. Am J Physiol 1998, 275(3 Pt 1):C711-731.
12. Martines A.M., Masereeuw R., Tjalsma H., et al. Iron metabolism in the pathogenesis of iron-induced kidney injury. Nat Rev Nephrol 2013, 9(7):385-398.
13. Haase M., Bellomo R., Haase-Fielitz A. Novel biomarkers, oxidative stress, and the role of labile iron toxicity in cardiopulmonary bypass-associated acute kidney injury. J Am Coll Cardiol 2010, 55(19):2024-2033.
14. Martensson J., Bell M., Oldner A., et al. Neutrophil gelatinase-associated lipocalin in adult septic patients with and without acute kidney injury. Intensive Care Med 2010, 36(8):1333-1340.
15. Martensson J., Bell M., Xu S., et al. Association of plasma neutrophil gelatinase-associated lipocalin (NGAL) with sepsis and acute kidney dysfunction. Biomarkers 2013, 18(4):349-356.
16. Martensson J., Glassford N.J., Jones S., et al. Urinary neutrophil gelatinase-associated lipocalin to hepcidin ratio as a biomarker of acute kidney injury in intensive care unit patients. Minerva Anestesiol 2014, [Epub ahead of print].
17. Linkermann A., Green D.R. Necroptosis. N Engl J Med 2014, 370(5):455-465.
18. Langenberg C., Wan L., Egi M., et al. Renal blood flow in experimental septic acute renal failure. Kidney Int 2006, 69(11):1996-2002.
19. Calzavacca P., May C.N., Bellomo R. Glomerular haemodynamics, the renal sympathetic nervous system and sepsis-induced acute kidney injury. Nephrol Dial Transplant 2014, 29(12):2178-2184.
20. Wan L., Langenberg C., Bellomo R., et al. Angiotensin II in experimental hyperdynamic sepsis. Crit Care 2009, 13(6):R190.
21. Ishikawa K., Wan L., Calzavacca P., et al. The effects of terlipressin on regional hemodynamics and kidney function in experimental hyperdynamic sepsis. PLoS One 2012, 7(2):e29693.
22. Ljungqvist A. Ultrastructural demonstration of a connection between afferent and efferent juxtamedullary glomerular arterioles. Kidney Int 1975, 8(4):239-244.
23. Casellas D., Mimran A. Shunting in renal microvasculature of the rat: a scanning electron microscopic study of corrosion casts. Anat Rec 1981, 201(2):237-248.
24. Prowle J.R., Kirwan C.J., Bellomo R. Fluid management for the prevention and attenuation of acute kidney injury. Nat Rev Nephrol 2014, 10(1):37-47.
25. Cruces P., Salas C., Lillo P., et al. The renal compartment: a hydraulic view. Intensive Care Med Exp 2014, 2:26.
26. Legrand M., Dupuis C., Simon C., et al. Association between systemic hemodynamics and septic acute kidney injury in critically ill patients: a retrospective observational study. Crit Care 2013, 17(6):R278.
27. Asfar P., Meziani F., Hamel J.F., et al. High versus low blood-pressure target in patients with septic shock. N Engl J Med 2014, 370(17):1583-1593.
28. Rivers E., Nguyen B., Havstad S., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345(19):1368-1377.
29. Dellinger R.P., Levy M.M., Rhodes A., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41(2):580-637.
30. Maitland K., Kiguli S., Opoka R.O., et al. Mortality after fluid bolus in African children with severe infection. N Engl J Med 2011, 364(26):2483-2495.
31. Yealy D.M., Kellum J.A., Huang D.T., et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med 2014, 370(18):1683-1693.
32. Peake S.L., Delaney A., Bailey M., et al. Goal-directed resuscitation for patients with early septic shock. N. Engl. J Med 2014, 371(16):1496-1506.
33. Bihari S., Prakash S., Bersten A.D. Post resuscitation fluid boluses in severe sepsis or septic shock: prevalence and efficacy (price study). Shock 2013, 40(1):28-34.
34. Glassford N.J., Eastwood G.M., Bellomo R. Physiological changes after fluid bolus therapy in sepsis: a systematic review of contemporary data. Crit Care 2014, 18:696.
35. Payen D., de Pont A.C., Sakr Y., et al. A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care 2008, 12(3):R74.
36. Grams M.E., Estrella M.M., Coresh J., et al. Fluid balance, diuretic use, and mortality in acute kidney injury. Clin J Am Soc Nephrol 2011, 6(5):966-973.
37. Bouchard J., Soroko S.B., Chertow G.M., et al. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int 2009, 76(4):422-427.
38. Boyd J.H., Forbes J., Nakada T.A., et al. Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med 2011, 39(2):259-265.
39. Russell J.A., Walley K.R., Singer J., et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008, 358(9):877-887.
40. Gordon A.C., Russell J.A., Walley K.R., et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med 2010, 36(1):83-91.
41. Sanyal A.J., Boyer T., Garcia-Tsao G., et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008, 134(5):1360-1368.
42. Chant C., Wilson G., Friedrich J.O. Anemia, transfusion, and phlebotomy practices in critically ill patients with prolonged ICU length of stay: a cohort study. Crit Care 2006, 10(5):R140.
43. Maynar Moliner J., Honore P.M., Sanchez-Izquierdo Riera J.A., et al. Handling continuous renal replacement therapy-related adverse effects in intensive care unit patients: the daily trauma concept. Blood Purif 2012, 34(2):177-185.
44. von Ahsen N., Muller C., Serke S., et al. Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients. Crit Care Med 1999, 27(12):2630-2639.
45. Marik P.E., Corwin H.L. Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med 2008, 36(9):2667-2674.
46. Rohde J.M., Dimcheff D.E., Blumberg N., et al. Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis. JAMA 2014, 311(13):1317-1326.
47. Holst L.B., Haase N., Wetterslev J., et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med 2014, 371(15):1381-1391.
48. Wald R., Shariff S.Z., Adhikari N.K., et al. The association between renal replacement therapy modality and long-term outcomes among critically ill adults with acute kidney injury: a retrospective cohort study. Crit Care Med 2014, 42(4):868-877.
49. Sun Z., Ye H., Shen X., et al. Continuous venovenous hemofiltration versus extended daily hemofiltration in patients with septic acute kidney injury: a retrospective cohort study. Crit Care 2014, 18(2):R70.
50. Schneider A.G., Bellomo R., Bagshaw S.M., et al. Choice of renal replacement therapy modality and dialysis dependence after acute kidney injury: a systematic review and meta-analysis. Intensive Care Med 2013, 39(6):987-997.
51. Bellomo R., Cass A., Cole L., et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009, 361(17):1627-1638.
52. Jun M., Bellomo R., Cass A., et al. Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal versus augmented level of replacement therapy study. Crit Care Med 2014, 42(8):1756-1765.
53. Payen D., Mateo J., Cavaillon J.M., et al. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med 2009, 37(3):803-810.
54. Vaara S.T., Korhonen A.M., Kaukonen K.M., et al. Fluid overload is associated with an increased risk for 90-day mortality in critically ill patients with renal replacement therapy: data from the prospective FINNAKI study. Crit Care 2012, 16(5):R197.
55. Lameire N., Kellum J.A. Contrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary (Part 2). Crit Care 2013, 17(1):205.
56. Palevsky P.M., Zhang J.H., O'Connor T.Z., et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008, 359(1):7-20.
57. Boussekey N., Chiche A., Faure K., et al. A pilot randomized study comparing high and low volume hemofiltration on vasopressor use in septic shock. Intensive Care Med 2008, 34(9):1646-1653.
58. Joannes-Boyau O., Honore P.M., Perez P., et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med 2013, 39(9):1535-1546.
59. Peters E., van Elsas A., Heemskerk S., et al. Alkaline phosphatase as a treatment of sepsis-associated acute kidney injury. J Pharmacol Exp Ther 2013, 344(1):2-7.
60. Pickkers P., Heemskerk S., Schouten J., et al. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Crit Care 2012, 16(1):R14.
61. Akinosoglou K., Alexopoulos D. Use of antiplatelet agents in sepsis: a glimpse into the future. Thromb Res 2014, 133(2):131-138.
62. Winning J., Neumann J., Kohl M., et al. Antiplatelet drugs and outcome in mixed admissions to an intensive care unit. Crit Care Med 2010, 38(1):32-37.
63. Eisen D.P. Manifold beneficial effects of acetyl salicylic acid and nonsteroidal anti-inflammatory drugs on sepsis. Intensive Care Med 2012, 38(8):1249-1257.
64. Chen J., Shetty S., Zhang P., et al. Aspirin-triggered resolvin D1 down-regulates inflammatory responses and protects against endotoxin-induced acute kidney injury. Toxicol Appl Pharmacol 2014, 277(2):118-123.
65. Allam R., Kumar S.V., Darisipudi M.N., et al. Extracellular histones in tissue injury and inflammation. J Mol Med 2014, 92(5):465-472.
66. Ranieri V.M., Thompson B.T., Barie P.S., et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012, 366(22):2055-2064.
67. Xu J., Zhang X., Pelayo R., et al. Extracellular histones are major mediators of death in sepsis. Nat Med 2009, 15(11):1318-1321.
68. Cruz D.N., Antonelli M., Fumagalli R., et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009, 301(23):2445-2452.
69. Klein D.J., Foster D., Schorr C.A., et al. The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial. Trials 2014, 15:218.